Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th

PALO ALTO, Calif. – January 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the 19th Annual BIO CEO & Investor Conference at 10:00 am ET on Monday, February 13, 2017, at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.

Eiger will also host one-on-one meetings with investors at the SunTrust Robinson Humphrey 2017 Orphan Drug Day conference on Tuesday, February 14, 2017, at the JW Marriott Essex House in New York City.

About Eiger
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Eiger BioPharmaceuticals

SOURCE Eiger Bio, Inc.
Investors: Andrew McDonald LifeSci Advisors, LLC, 646-597-6987, andrew@lifesciadvisors.com

PDF Icon

See More Press Releases